NUCLEOLIN and cancer: The profile of binding of anti-nucleolin VHH constructs to 4T1 cancer cell line, relative to the parental VHH (p < 0.01 for CDR3-grafted VHHs, at 100 nM and p < 0.001 for all anti-nucleolin VHHs, at 1000 nM), was similar to the one reported for MDA-MB-435S (Fig. 2b).